<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01219452</url>
  </required_header>
  <id_info>
    <org_study_id>MSCKX002</org_study_id>
    <nct_id>NCT01219452</nct_id>
  </id_info>
  <brief_title>Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy</brief_title>
  <official_title>Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to determine whether intramuscular injection of umbilical cord
      mesenchymal stem cells can improve the ventricular function of children with idiopathic
      dilated cardiomyopathy(IDCM); Secondary end-points will be: 1)To explore the possible
      mechanism of the improvement of ventricular function in children with IDCM and 2) to
      evaluate the safety of intramuscular injection of umbilical cord mesenchymal stem cell.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with Idiopathic dilated cardiomyopathy class II to III NYHA with ejection fraction
      over 20% were selected for phase II clinical trial, umbilical cord mesenchymal stem cells
      were injected into limb muscle and followed for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>echocardiography</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h HOLTER</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum BNP,TNI,HGF„ÄÅLIF and G/M-CSF</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The expression level of c-kit,CD31,CD133 on peripheral blood mononuclear cells</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramuscular injection of umbilical cord mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cells</intervention_name>
    <description>Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.</description>
    <arm_group_label>umbilical cord mesenchymal stem cells</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of both genders with established clinical and echocardiographic diagnosis of
             dilated cardiomyopathy whose parents accept to participate in the trail.

          -  They should have symptoms and /or signs of heart failure, despite optimized medical
             treatment.

          -  Ejection fraction of left ventricular should be less than 50%, but more than 20%.

        Exclusion Criteria:

          -  associate coronary artery disease.

          -  any history or suspicion of a toxic , pharmacologic or deposit etiology.

          -  associated malignant or pre -malignant systemic disease.

          -  associated hematologic disorder.

          -  a history of sustained ventricular tachycardia or fibrillation.

          -  a history of syncope during the previous year, or with an active infectious disease
             or positive tests to viral disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zipu li, MD Phd</last_name>
    <role>Study Director</role>
    <affiliation>The Affiliated Hospital of Medical College of Qingdao University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianxia Hu, MD</last_name>
    <phone>86-0532-82911676</phone>
    <email>qdyxyhjx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Gao, MS</last_name>
    <phone>86-0532-82911676</phone>
    <email>honggaogloria@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cell Research Center of Medical School Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>October 27, 2010</lastchanged_date>
  <firstreceived_date>October 12, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Qingdao University</name_title>
    <organization>Organization: Stem Cell Research Center of Medical School Hospital of Qingdao University</organization>
  </responsible_party>
  <keyword>Dilated Cardiomyopathy</keyword>
  <keyword>Umbilical cord</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Children</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
</clinical_study>
